Synthetic Cannabinoids Cause Far More Severe Side Effects Than Natural Cannabis

From 944 studies screened, 49 met inclusion criteria (2010-2022). Synthetic cannabinoids primarily affected neurological and cardiovascular systems, with common symptoms including seizures, altered consciousness, tachycardia, and hypertension. Hospital and ICU admissions varied reflecting toxicity complexity. Compared to cannabis, SC use was linked to more severe cardiovascular and neurological complications. Rare complications included thromboembolic events and immune thrombocytopenic purpura. Participants were predominantly young adult males (ages 12-72).

Systematic review following PRISMA guidelines across PubMed, Embase, and Lilacs databases. 944 studies screened; 49 published 2010-2022 included. Focused on clinical effects associated with SC use, excluding case reports, other reviews, animal studies, and those on psychiatric symptoms or therapeutic uses only.

Synthetic cannabinoids are often marketed as legal alternatives to cannabis, but their 100-fold higher receptor affinity translates to dramatically more dangerous clinical outcomes. This comprehensive review documents the full spectrum of adverse effects, providing evidence for public health campaigns and emergency medicine protocols.

As synthetic cannabinoids evolve rapidly to evade regulation, the clinical consequences documented here underscore the importance of distinguishing between natural cannabis and synthetic alternatives in both public health messaging and emergency care. The severity of SC toxicity argues against treating them as equivalent to cannabis in policy or clinical contexts.

Heterogeneous study designs and populations limit direct comparisons. Excluded psychiatric-only outcomes, potentially underestimating total burden. Rapid emergence of new SC compounds means findings may not cover newest variants. Publication bias toward severe cases may overestimate typical toxicity.